220 related articles for article (PubMed ID: 29116166)
1. Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D).
Gurney ME; Cogram P; Deacon RM; Rex C; Tranfaglia M
Sci Rep; 2017 Nov; 7(1):14653. PubMed ID: 29116166
[TBL] [Abstract][Full Text] [Related]
2. Effects of chronic inhibition of phosphodiesterase-4D on behavior and regional rates of cerebral protein synthesis in a mouse model of fragile X syndrome.
Rosenheck M; Sheeler C; Saré RM; Gurney ME; Smith CB
Neurobiol Dis; 2021 Nov; 159():105485. PubMed ID: 34411704
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial.
Berry-Kravis EM; Harnett MD; Reines SA; Reese MA; Ethridge LE; Outterson AH; Michalak C; Furman J; Gurney ME
Nat Med; 2021 May; 27(5):862-870. PubMed ID: 33927413
[TBL] [Abstract][Full Text] [Related]
4. PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome.
Choi CH; Schoenfeld BP; Weisz ED; Bell AJ; Chambers DB; Hinchey J; Choi RJ; Hinchey P; Kollaros M; Gertner MJ; Ferrick NJ; Terlizzi AM; Yohn N; Koenigsberg E; Liebelt DA; Zukin RS; Woo NH; Tranfaglia MR; Louneva N; Arnold SE; Siegel SJ; Bolduc FV; McDonald TV; Jongens TA; McBride SM
J Neurosci; 2015 Jan; 35(1):396-408. PubMed ID: 25568131
[TBL] [Abstract][Full Text] [Related]
5. Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.
Gurney ME; Nugent RA; Mo X; Sindac JA; Hagen TJ; Fox D; O'Donnell JM; Zhang C; Xu Y; Zhang HT; Groppi VE; Bailie M; White RE; Romero DL; Vellekoop AS; Walker JR; Surman MD; Zhu L; Campbell RF
J Med Chem; 2019 May; 62(10):4884-4901. PubMed ID: 31013090
[TBL] [Abstract][Full Text] [Related]
6. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
[TBL] [Abstract][Full Text] [Related]
7. R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.
Qin M; Huang T; Kader M; Krych L; Xia Z; Burlin T; Zeidler Z; Zhao T; Smith CB
Int J Neuropsychopharmacol; 2015 Mar; 18(9):. PubMed ID: 25820841
[TBL] [Abstract][Full Text] [Related]
8. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.
Bilousova TV; Dansie L; Ngo M; Aye J; Charles JR; Ethell DW; Ethell IM
J Med Genet; 2009 Feb; 46(2):94-102. PubMed ID: 18835858
[TBL] [Abstract][Full Text] [Related]
9. Astrocytic Contributions to Synaptic and Learning Abnormalities in a Mouse Model of Fragile X Syndrome.
Hodges JL; Yu X; Gilmore A; Bennett H; Tjia M; Perna JF; Chen CC; Li X; Lu J; Zuo Y
Biol Psychiatry; 2017 Jul; 82(2):139-149. PubMed ID: 27865451
[TBL] [Abstract][Full Text] [Related]
10. Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice.
Zhang C; Xu Y; Chowdhary A; Fox D; Gurney ME; Zhang HT; Auerbach BD; Salvi RJ; Yang M; Li G; O'Donnell JM
Neuropsychopharmacology; 2018 Oct; 43(11):2299-2309. PubMed ID: 30131563
[TBL] [Abstract][Full Text] [Related]
11. Behavioral Phenotype of Fmr1 Knock-Out Mice during Active Phase in an Altered Light/Dark Cycle.
Saré RM; Levine M; Smith CB
eNeuro; 2016; 3(2):. PubMed ID: 27294193
[TBL] [Abstract][Full Text] [Related]
12. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome.
Spencer CM; Alekseyenko O; Serysheva E; Yuva-Paylor LA; Paylor R
Genes Brain Behav; 2005 Oct; 4(7):420-30. PubMed ID: 16176388
[TBL] [Abstract][Full Text] [Related]
13. Characterization of ultrasonic vocalizations of Fragile X mice.
Belagodu AP; Johnson AM; Galvez R
Behav Brain Res; 2016 Sep; 310():76-83. PubMed ID: 27142239
[TBL] [Abstract][Full Text] [Related]
14. Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice.
Santini E; Huynh TN; Longo F; Koo SY; Mojica E; D'Andrea L; Bagni C; Klann E
Sci Signal; 2017 Nov; 10(504):. PubMed ID: 29114037
[TBL] [Abstract][Full Text] [Related]
15. Behavioral effects of chronic stress in the Fmr1 mouse model for fragile X syndrome.
Lemaire-Mayo V; Subashi E; Henkous N; Beracochea D; Pietropaolo S
Behav Brain Res; 2017 Mar; 320():128-135. PubMed ID: 27939692
[TBL] [Abstract][Full Text] [Related]
16. Fragile X mice have robust mGluR5-dependent alterations of social behaviour in the Automated Tube Test.
de Esch CE; van den Berg WE; Buijsen RA; Jaafar IA; Nieuwenhuizen-Bakker IM; Gasparini F; Kushner SA; Willemsen R
Neurobiol Dis; 2015 Mar; 75():31-9. PubMed ID: 25562659
[TBL] [Abstract][Full Text] [Related]
17. Behavioral abnormalities in the Fmr1-KO2 mouse model of fragile X syndrome: The relevance of early life phases.
Gaudissard J; Ginger M; Premoli M; Memo M; Frick A; Pietropaolo S
Autism Res; 2017 Oct; 10(10):1584-1596. PubMed ID: 28590057
[TBL] [Abstract][Full Text] [Related]
18. Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
Gross C; Banerjee A; Tiwari D; Longo F; White AR; Allen AG; Schroeder-Carter LM; Krzeski JC; Elsayed NA; Puckett R; Klann E; Rivero RA; Gourley SL; Bassell GJ
Neuropsychopharmacology; 2019 Jan; 44(2):324-333. PubMed ID: 30061744
[TBL] [Abstract][Full Text] [Related]
19. Hyperactive locomotion in a
Kashima R; Redmond PL; Ghatpande P; Roy S; Kornberg TB; Hanke T; Knapp S; Lagna G; Hata A
Sci Signal; 2017 May; 10(477):. PubMed ID: 28465421
[TBL] [Abstract][Full Text] [Related]
20. Social behavior phenotypes in fragile X syndrome, autism, and the Fmr1 knockout mouse: theoretical comment on McNaughton et al. (2008).
Brodkin ES
Behav Neurosci; 2008 Apr; 122(2):483-9. PubMed ID: 18410188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
